Last reviewed · How we verify
mRNA-1283.222
mRNA-1283.222 is a mRNA vaccine Biologic drug developed by ModernaTX, Inc.. It is currently in Phase 3 development for COVID-19.
mRNA-1283.222 is a messenger RNA-based vaccine that encodes for a specific protein to stimulate an immune response.
mRNA-1283.222 is an intervention being studied in a clinical trial to prevent COVID-19 in participants aged 12 and older. The exact mechanism of mRNA-1283.222 is unknown.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline. -
Big-pharma sponsor
+3.0pp
ModernaTX, Inc. is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | mRNA-1283.222 |
|---|---|
| Sponsor | ModernaTX, Inc. |
| Drug class | mRNA vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
This vaccine works by introducing a piece of genetic material that instructs cells to produce a specific protein, which in turn triggers an immune response. This immune response helps the body recognize and fight against the target disease or condition.
Approved indications
- COVID-19
Common side effects
- Pain, redness, or swelling at the injection site
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mRNA-1283.222 CI brief — competitive landscape report
- mRNA-1283.222 updates RSS · CI watch RSS
- ModernaTX, Inc. portfolio CI
Frequently asked questions about mRNA-1283.222
What is mRNA-1283.222?
How does mRNA-1283.222 work?
What is mRNA-1283.222 used for?
Who makes mRNA-1283.222?
What drug class is mRNA-1283.222 in?
What development phase is mRNA-1283.222 in?
What are the side effects of mRNA-1283.222?
Related
- Drug class: All mRNA vaccine drugs
- Manufacturer: ModernaTX, Inc. — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for COVID-19
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing